Sep 22, 2026
Novartis licenses BoomRay radioligand asset for $900M
Novartis has licensed a preclinical radioligand therapy from China's BoomRay Pharmaceuticals in a deal potentially worth up to $900 million, further expanding its oncology portfolio. This acquisition reinforces Novartis's significant investment in radioligand therapies, a field it entered with the acquisition of Advanced Accelerator Applications and Endocyte. The deal follows another major radiopharma transaction involving Telix Pharmaceuticals and ITM.
Company relevance
100.00%
Company sentiment
Somewhat-Bullish
Overall sentiment
Somewhat-Bullish
Sep 16, 2026
Novartis halts ALS drug development after mid-stage trial failure
Novartis has stopped the development of its experimental amyotrophic lateral sclerosis (ALS) drug, VHB937 (lifonebart), following its failure to meet primary and secondary endpoints in a mid-stage trial. This setback adds to several other recent disappointments for the Swiss drugmaker, including issues with a heart drug, a muscle-wasting drug, and its rap-cel cell therapy, leading to increased scrutiny of its drug pipeline. Novartis is also investigating the drug for Alzheimer's disease, with a mid-stage trial currently recruiting patients.
Company relevance
100.00%
Company sentiment
Somewhat-Bearish
Overall sentiment
Somewhat-Bearish
Sep 16, 2026
Novartis experimental drug for ALS fails in another pipeline hit
Novartis announced a setback in its pipeline as its experimental drug for Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, failed. ALS is a rapidly progressing condition leading to paralysis, difficulty swallowing, and breathing issues. This failure marks another hit for the company's drug development efforts.
Company relevance
100.00%
Company sentiment
Bearish
Overall sentiment
Bearish